COMMUNIQUÉS West-GlobeNewswire

Inventiva publie ses informations financières préliminaires du premier semestre 2025¹
29/07/2025
Trésorerie et équivalents de trésorerie de 122,1 millions d’euros et 24,6 millions d’euros de dépôts à court terme 2 au 30 juin 2025 Chiffre d’affaires de 4,5 millions d’euros au premier semestre 2025 Daix (France), New [...]
Inventiva Reports Preliminary 2025 First-Half Financial Information¹
29/07/2025
Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits 2 as of June 30, 2025 Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City (New York, United States), July 29, [...]
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints
29/07/2025
- Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved Therapies with [...]
Larimar Therapeutics Announces Proposed Underwritten Public Offering
29/07/2025
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
29/07/2025
IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter [...]
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
29/07/2025
- Appointed Dr. Roger Sidhu as Chief Medical Officer - - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic [...]
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
29/07/2025
IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing [...]
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
29/07/2025
SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4: [...]
LifeMD to Report Second Quarter 2025 Financial Results on August 5
29/07/2025
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD) , a leading provider of virtual primary care services, announces that it will report financial results for the three and six months ended June 30, [...]
Iridex to Report Second Quarter 2025 Financial Results on August 12, 2025
29/07/2025
MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
Ceribell to Participate in the Canaccord Genuity 45th Annual Growth Conference
29/07/2025
SUNNYVALE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025
29/07/2025
MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report [...]
Teladoc Health Reports Second Quarter 2025 Results
29/07/2025
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended June 30, 2025 (“Second Quarter 2025”). Unless [...]
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
29/07/2025
– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose [...]
DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025
29/07/2025
Châtillon, France, le 29 juillet 2025 DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT-CUSIP : [...]
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
29/07/2025
Châtillon, France, July 29, 2025 DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a [...]
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
29/07/2025
ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
29/07/2025
DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”) , a global leader in innovations for active healing, today announced that it will report financial results for [...]
DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation
29/07/2025
Châtillon, France, le 29 juillet 2025 DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : [...]

Pages